View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corp...

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with new scientific partnership with the National Cancer Institute and further collaboration for new costimulatory switch protein with Helmholtz MunichUpdates to strategy going forward to develop both TCR-T therapies and additional, non-autol...

 PRESS RELEASE

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Ther...

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. Members of Medigene's management team will join a fireside chat and will be available for virtual one-on-one meetings with registered investors. ---  end of press rele...

 PRESS RELEASE

Medigene AG to report full year 2023 financial results on March 28, 2...

Medigene AG to report full year 2023 financial results on March 28, 2024 Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am ET. Full deta...

 PRESS RELEASE

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addit...

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting Planegg/Martinsried, March 6, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held...

 PRESS RELEASE

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to...

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo Planegg/Martinsried, March 4, 2024. (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighte...

 PRESS RELEASE

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach ...

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlight key parts of Medigene’s proprietary End-to-End Platform by offering multiple solutions to address the challenges in TCR-T therapy development for treatment of solid tumors Planegg/Martinsrie...

 PRESS RELEASE

Medigene to Present at Upcoming Conferences

Medigene to Present at Upcoming Conferences Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024 Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof...

 PRESS RELEASE

Medigene Announces Indication Selection for the Clinical Development ...

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB Clinical development in both orphan and more common cancer indications addresses high unmet medical need in large patient populations Planegg/Martinsried, Febru...

 PRESS RELEASE

Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Confer...

Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024. J.P. Morgan Healthcare Conference Date: January 8-11, 2024Location: The Westin St. Francis Hotel, San Francisco, CA Members of Medigene’s management team will...

 PRESS RELEASE

Medigene AG Announces Prioritization of Pipeline and Resource Allocati...

Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway Lead program MDG1015 on track for CTA/IND approval in 2H 2024Prioritization of pipeline to accelerate the advancement of Medigene’s maturing KRAS-libraryProjected cash runway extended to Q1 2025. Exploring financing options to extend cash runway into 2026 and beyond Planegg/Martinsried, November 21, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies fo...

 PRESS RELEASE

Medigene amends 2023 financial guidance

Medigene amends 2023 financial guidance Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2023. The Company maintains its guidance on expected revenues to be between EUR 5 and 7 million in 2023 (unchanged). The Company continuously optimizes its resource allocation based on business demands. Due to the challenging capital m...

 PRESS RELEASE

Medigene presents new data for MDG2011, the first TCR in a novel KRAS ...

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11 Planegg/Martinsried, November 4, 2023. (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents novel preclinical data of their MDG2011 program lead candidates which are optimal affinity Kirsten rat sarcoma viral oncogene homologue mutation (mKRAS)-specific T ce...

 PRESS RELEASE

Medigene Reports Financial Results and Corporate Update for Q3 2023

Medigene Reports Financial Results and Corporate Update for Q3 2023 Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for technologies in our End-to-End Platform Guidance confirmed; cash runway maintained through Q4 2024 Planegg/Martinsried, October 26, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, t...

 PRESS RELEASE

Medigene presents first pre-clinical data of optimal affinity TCR targ...

Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing Planegg/Martinsried, October 23, 2023. (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents data showing significantly enhanced T cell activity when combining the PD1-41BB costimulatory switch protein (CSP) with recombinant T cell receptors (rTCR) not only when directed at the c...

 PRESS RELEASE

Medigene to present new pre-clinical data for pipeline TCR-T therapies...

Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023 Planegg/Martinsried, October 16, 2023. (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the ESMO Congress 2023 being held on October 20-24, 2023, in Madrid, Spain. The data to be presented shows that optimal affinity T cell receptors (TCRs) when combined with Medigene’s PD1-41BB costimulatory  switch protein (CSP), provides strong protection of T ...

 PRESS RELEASE

Medigene AG Secures European Patent for its PD1-41BB Costimulatory S...

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene. ...

 PRESS RELEASE

Medigene AG Announces Lead Selection for MDG2011 Representing the Firs...

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-4...

 PRESS RELEASE

Medigene AG to present at the Baader Investment Conference 2023

Medigene AG to present at the Baader Investment Conference 2023 Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023. Corporate presentation - Baader Investment Conference 2023 Date and time: Monday, September 18, 2023, 2:10 pm – 2:50 pm (local time)Location: Sofitel Munich Bayerpost in MunichSpeaker: Dr. Se...

 PRESS RELEASE

Medigene AG to present at the H.C. Wainwright 25th Annual Global Inves...

Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference Planegg/Martinsried, September 5, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023, held at the Lotte New York Palace Hotel in New York City. H.C. Wainwright 25th Annual Global Investment Conference 2023 Date and time: Monday, September 11, 2023, 4.30pm – 5pm (local tim...

 PRESS RELEASE

Medigene presents rationale for combining its 3S TCRs with enhancement...

Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 8th CAR-TCR Summit in Boston on August 30, 2023. The title of the presentation is “Improving TCR-T Therapeutic Persistence and Efficacy with Switch Receptors.”  Professor Dolores Sch...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch